GSK makes new drug submission for depemokimab in Canada
GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific conditions.
The first proposed indication is for the use as an add-on maintenance treatment for asthma in individuals aged 12 years and above with type 2 inflammation marked by an eosinophilic phenotype.
The second is for treating adults with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
Depemokimab targets interleukin-5 (IL-5), which plays a crucial role in type 2 inflammation.
GSK's submission is supported by the positive Phase III SWIFT and ANCHOR trial data.
These trials have demonstrated that the antibody could provide sustained inhibition of a key disease driver and assist in achieving clinical outcomes with two injections annually.
The extended half-life and binding affinity of the antibody support a dosing regimen of a single injection every six months.
Patients with CRSwNP often suffer from symptoms such as loss of smell, facial pain, nasal obstruction, sleep disturbance, nasal discharge and infections.
The effectiveness and safety of the antibody are still being investigated, and it has neither been granted any authorisation nor approved for use in any nation at present.
GSK Canada country medical director Michelle Horn stated: 'The combined submission for asthma and CRSwNP marks a significant step toward addressing the unmet needs of patients.
'Backed by strong clinical evidence, depemokimab has the potential to become the first ultra-long-acting biologic offering patients sustained inhibition of IL-5, a key driver of their disease with twice-yearly dosing, and represents a promising advancement for patients and physicians alike.'
In November 2024, GSK secured Health Canada's approval for Ojjaara (momelotinib) to treat myelofibrosis in adults with moderate-to-severe anaemia.
"GSK makes new drug submission for depemokimab in Canada" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
an hour ago
- Hamilton Spectator
Biognosys Launches Spectronaut 20 and SpectroMine 5, Setting New Benchmarks in Immunopeptidomics
ZURICH and BOSTON, May 30, 2025 (GLOBE NEWSWIRE) — Biognosys, a global leader in mass spectrometry-based proteomics solutions, announces the launch of Spectronaut® 20 and SpectroMine™ 5 at the ASMS 2025 Annual Conference, taking place June 1–5 in Baltimore, MD. These major software updates mark significant technological advances in unspecific search performance, immunopeptidomics, and cloud-ready proteomics workflows. At the core of the new releases is Kuiper, Biognosys' novel search engine, powered by proprietary prediction models specifically optimized for unspecific searches. Kuiper delivers record-breaking peptide identifications, especially for immunopeptidomics applications. Key Features of Spectronaut® 20: Kuiper also powers SpectroMine™ 5, Biognosys' latest release for DDA-based proteomics, now offering significantly enhanced identification performance. With newly added Linux support, SpectroMine joins Spectronaut in enabling high-throughput proteomics data analysis in cloud and high-performance computing (HPC) environments—enabling scalable, next-generation research workflows. The applications of Biognosys' next-generation software will be highlighted through multiple scientific posters, two breakfast seminars, and workshop participations. These include two joint presentations with Greywolf Therapeutics on advanced immunopeptidomics workflows, as well as contributions to a workshop on best-practice reporting guidelines for DIA data. Biognosys will also present its latest technological innovation, the P2 Enrichment System—a robust, nanoparticle-based plasma workflow offering unprecedented depth, reproducibility, and throughput in plasma proteomics. Originally introduced at ASMS 2024, the P2 system will be featured in a new scientific poster and in a presentation by collaborators from Johns Hopkins School of Medicine. Their research demonstrates P2's real-world application in a clinical study on circulating biomarker discovery for advancing early detection of neurodegenerative diseases. In addition, Biognosys has been invited to deliver an oral presentation on Proteoverse® Digital Proteome, the company's proprietary multi-tissue, multi-species proteome expression atlas. As one of the most comprehensive resources of its kind it provides powerful insights into the proteomic landscape across human and preclinical species, supporting cutting-edge research in drug discovery and translational science. 'Immunopeptidomics is key to understanding how our therapeutics are making a difference for patients. Spectronaut 20 empowers us to leverage complex datasets with greater speed and depth, delivering critical insights into MHC-I antigen modulation and its effects on immune recognition,' said Daniel Green, Ph.D., Head of Bioinformatics at Greywolf Therapeutics. 'The P2 Enrichment System from Biognosys was seamlessly transferred to our lab at the Broad Institute. We were impressed by the clarity and robustness of the protocols, as well as the exceptional performance of the technology across our sample sets,' said Steven A. Carr, Ph.D., Senior Director of Proteomics and Institute Scientist at the Broad Institute of MIT and Harvard. For more information on Biognosys' scientific presence at ASMS 2025, please visit: About Spectronaut® Spectronaut is Biognosys' flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics. The software employs advanced Search and Artificial Intelligence (AI) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multi-dimensional insights into protein expression, function, and structure across all major biological species and sample types. For more information, visit About Biognosys Biognosys is a leading contract research organization (CRO) specializing in proteomics services for early-stage R&D through clinical trial biomarker monitoring. Partnering with the most innovative biotech and pharmaceutical companies worldwide, Biognosys utilizes unique, patented technologies and high-resolution mass spectrometry to quantify thousands of proteins with unmatched precision, depth, and throughput. With laboratories near Zuerich, Switzerland and Boston, Massachusetts, Biognosys combines scientific expertise and next-generation proteomics to accelerate drug discovery and development, and supports translational and preclinical research, and clinical trials for precision medicine. Learn more at Media Contacts Kristina Beeler, Ph.D. Chief Product Development and Marketing Officer
Yahoo
12 hours ago
- Yahoo
Farrell couple tells story of survival and loss 40 years after deadly tornado
FARRELL, Pa. (WKBN) – This Saturday marks 40 years since one of the deadliest tornado outbreaks in U.S. history. On May 31, 1985, a powerful F-5 tornado tore through parts of Ohio and Pennsylvania, leaving a path of devastation and heartbreak in its wake. One of the hardest-hit communities was Farrell, Pennsylvania, where lives were changed forever in just a matter of seconds. Gerald 'Bugs' Multari survived the storm, but lost a dear friend. Multari keeps a trained eye on the sky these days because he knows just how quickly things can change. 'It was seconds, it really was. It couldn't have been more than half a minute or so, it was gone,' he said. A spring day in 1985 that turned deadly, the violent tornado outbreak ripped across the area. Forty years later, the scars remain etched into the hearts of people, like Multari, who survived. 'There were no tornado sirens whatsoever,' he said. Multari and his wife, Kathy, were cheering on their son at a Little League game that day when the sky darkened and the storm rolled through. He threw himself on top of his children, shielding them with a metal sign. Kathy rode out the storm in the concession stand. 'All you saw was debris flying out of the top,' Multari said. David Kostka, affectionately known as 'Davey,' was a longtime friend of the Multaris, coaching third base that day for his son's team. Kostka was killed by the storm. A memorial at the corner of Roemer Boulevard and Park Avenue now honors his life and sacrifice. 'It's comforting but also sad. It looks like he's looking right at you,' Kathy Multari said. The trauma ran deep as the family struggled to cope with the loss. 'Our daughter had to have counseling afterwards, just with the tornado and that was her first close death that she experienced, because he was like an uncle to our kids,' Kathy Multari said. This quiet tribute is a spot Gerald Multari has visited frequently in the years since Kostka's death. 'I passed that every day and I would speak to him. I told him I loved him, and missed him and everything,' he said. This weekend marks 40 years since the sky opened up over Farrell but the time hasn't erased those memories — it's just given them space to remember. 'I cried, I think we all did,' Multari said. 'You just can't get over it. You just can't get over that.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
15 hours ago
- Yahoo
Parker Institute Showcases Breakthroughs in Immunotherapy at ASCO 2025 as CEO Dr. Karen Knudsen Receives Prestigious Honor
Glioblastoma survival extends to 14.6 months; dual-target CAR T shrinks tumors in 85% of patients—milestone results among 50+ presentations across the PICI Network CHICAGO, May 29, 2025--(BUSINESS WIRE)--As the global oncology community gathers for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30–June 3), the Parker Institute for Cancer Immunotherapy (PICI) is demonstrating how bold science, accelerated through collaborative networks, can drive meaningful progress where patients need it most. At a pivotal moment when scientific breakthroughs in immunotherapy are arriving alongside heightened pressure for faster, smarter impact, PICI's integrated model shows how to compress timelines from discovery to patient care. PICI's presence spans more than 50 presentations including 16 oral sessions, 30+ poster sessions, 10 e-papers and a featured clinical science symposium. This volume reflects not only the strength of the PICI network but also a unique ability to support promising work early and help carry it across the finish line, from foundational discoveries to practice-changing trials. Glioblastoma Breakthroughs: New Hope for Cancer's Most Formidable Challenge After decades of limited progress in glioblastoma, where median survival has hovered around one year, multiple PICI-supported teams are reporting clinical responses that suggest the field may be turning a corner. These advances demonstrate how collaboration, persistence and innovation can converge on even the most intractable problems: Stanford Medicine researchers achieved median overall survival of 14.6 months in recurrent glioblastoma patients using B7H3 CAR T cells delivered directly to the brain via dual Ommaya reservoirs. The Phase 1 study established a recommended Phase 2 dose and demonstrated manageable inflammation using IL-1 blockade, offering a tangible advance in a cancer where meaningful clinical progress has long remained elusive. (Crystal Mackall, MD, Director of the PICI Center at Stanford; Michelle Monje, MD, PhD — Abstract #2018) University of Pennsylvania investigators reported tumor shrinkage in 85% of evaluable patients using bivalent CAR T-cell therapy targeting EGFR and IL13Rα2 in recurrent glioblastoma. Delivered into the cerebroventricular space without lymphodepletion, the engineered T cells persisted in cerebrospinal fluid and blood for up to one year, marking an encouraging step toward sustained response and long-term disease management. (Carl June, MD, Director of the PICI Center at Penn; Donald O'Rourke, MD — Abstract #102) UCSF and Memorial Sloan Kettering researchers identified more than 700 glioma-specific, splice-derived neoantigens using the SNIPP antigen discovery platform. These targets elicited CD8+ T-cell responses in vitro and many were conserved across tumors, opening the door to scalable, potentially off-the-shelf TCR-based therapies. (Hideho Okada, MD, PhD, UCSF — Abstract #2519) Leadership Recognition: PICI CEO Receives ASCO's Highest Honor Dr. Karen Knudsen, PICI's CEO, will receive the Allen S. Lichter Visionary Leader Award during ASCO's opening session, recognizing a career spent building bridges from bench to patient and helping reshape how academic institutions, nonprofits and companies move from insight to implementation. Saturday, May 31, 9:45 AM–12:00 PM CDT, Room N - Hall B1 Dr. Knudsen will also join Endpoints News for a live discussion on research acceleration, regulatory pace and how PICI's model aligns research, policy and investment with the realities facing patients today. Wednesday, June 4, 10:35 AM CDT, Endpoints Stage Network-Wide Impact: Where Discovery Meets Delivery PICI-supported science appears across the ASCO agenda, tackling critical questions in high-burden cancers through studies connected by a framework that enables speed, coordination and clinical relevance. These presentations reflect a hallmark of the PICI approach: compressing the distance between new insight and patient impact, often turning early-stage ideas into clinical action within just a few years. Melanoma Advances DREAMseq Final Results: Optimal treatment sequencing in BRAF-mutant metastatic melanoma (Jedd Wolchok, MD, PhD, Weill Cornell; Antoni Ribas, MD, PhD, UCLA — Abstract #9506) Quadruple Immunotherapy: IL-6 blockade combined with checkpoint inhibitors in advanced melanoma (F. Stephen Hodi, MD, Dana-Farber — Abstract #9510) Neoadjuvant Strategy: Pembrolizumab in clinical stage IIB/C melanoma (Alexander Huang, MD, University of Pennsylvania — Abstract #9502) Prostate Cancer Innovation COMRADE Trial: Olaparib plus radium-223 in castration-resistant prostate cancer with bone metastases (Eliezer Van Allen, MD, Dana-Farber — Abstract #5007) C3NIRA Trial: Triplet chemo-immunotherapy induction followed by PARP inhibitor maintenance (Padmanee Sharma, MD, PhD, MD Anderson — Abstract #5008) Breast and Lung Cancer Precision Strategies NeoSTAR Trial: Response-guided neoadjuvant sacituzumab govitecan plus pembrolizumab in early triple-negative breast cancer (Elizabeth Mittendorf, MD, PhD, Dana-Farber — Abstract #511) ADRIATIC Correlatives: Genomic analysis of long-term responders in limited-stage small cell lung cancer (David Barbie, MD, Dana-Farber — Abstract #8014) Translational Platforms INCIPIENT Trial: CARv3-TEAM-E immunological correlates in recurrent glioblastoma (Marcela Maus, MD, PhD, Massachusetts General Hospital — Abstract #2008) BRCA1/2 DNA Vaccines: Plasmid-based immunotherapy platform with and without IL-12 (Robert Vonderheide, MD, DPhil, University of Pennsylvania — Abstract #10505) About the Parker Institute for Cancer Immunotherapy The Parker Institute for Cancer Immunotherapy (PICI) accelerates breakthrough immune therapies from discovery to patient impact through a collaborative network of the nation's top cancer centers. Founded in 2016 through the vision of Sean Parker, PICI unites leading institutions in a translational engine built for speed, coordination and clinical relevance. Unlike traditional research models, PICI goes beyond discovery by actively advancing promising innovations through clinical testing, company formation, incubation and commercialization. PICI supports high-risk, high-reward science with shared goals, data and infrastructure, helping compress timelines from laboratory discovery to patient access. The institute has supported more than 1,000 investigators across its network and created a portfolio of 17 biotech ventures with over $4 billion in raised capital. By integrating scientific excellence with entrepreneurial execution, PICI is reimagining how cures are made and accelerating their path to the people who need them most. Learn more at Follow #PICIatASCO for updates throughout the meeting. View source version on Contacts Media Contact: Eric McKeebyHead of Communications & MarketingParker Institute for Cancer Immunotherapy(646) 522-4605emckeeby@
